Tag Archives: Andre Rancourt

GrowPros

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

OTTAWA, Ontario, Jan. 2, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors”).

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

OTTAWA, Ontario July 24, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

OTTAWA, Ontario, July 5, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug.

Aphria

Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials

OTTAWA, Ontario, Dec. 6, 2016 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (OTC PINK:GRPOF) is conducting a non-brokered private placement with Aphria Inc. (OTCQB:APHQF).


Top